BioInvent International AB's quarterly market cap
increased
from Sep. 2023 (kr1,097.62 Mil) to Dec. 2023 (kr1,247.65 Mil) but then
declined
from Dec. 2023 (kr1,247.65 Mil) to Mar. 2024 (kr1,118.67 Mil).
BioInvent International AB's annual market cap
declined
from Dec. 2021 (kr2,701.36 Mil) to Dec. 2022 (kr2,082.22 Mil) and
declined
from Dec. 2022 (kr2,082.22 Mil) to Dec. 2023 (kr1,247.65 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioInvent International AB's Enterprise Value for Today is kr691.03 Mil.
BioInvent International AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioInvent International AB's Market Cap
For the Biotechnology subindustry, BioInvent International AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Market Cap distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Market Cap falls into.
BioInvent International AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (OSTO:BINV) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioInvent International AB Market Cap Related Terms
Thank you for viewing the detailed overview of BioInvent International AB's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BioInvent International AB (OSTO:BINV) Business Description
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:BINV has been successfully added to your 